Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries

  title={Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries},
  author={Carlo Giaquinto and G{\'e}raldine Dominiak-Felden and Pierre van Damme and Tin Tin Htar Myint and Yvonne Maldonado and Vana Spoulou and Thomas Christopher Mast and Mary A Staat},
  journal={Human Vaccines},
  pages={734 - 748}
The pentavalent rotavirus (RV) vaccine RotaTeq™ has been available in industrialized countries since 2006. Several studies have been conducted to evaluate the benefit of RV vaccination under routine conditions of use. A systematic review of all publicly available data from RotaTeq™ vaccine-effectiveness and vaccination-impact studies in the USA, Europe and Australia between 2006 and February 2010 was undertaken. Depending on the population studied, effectiveness of up to 100% (95% confidence… 
Impact and Effectiveness of RotaTeq® Vaccine Based on 3 Years of Surveillance Following Introduction of a Rotavirus Immunization Program in Finland
Severe RVGE requiring hospitalization was virtually eliminated in vaccine-eligible children in the 3 years following implementation of universal RotaTeq vaccination in Finland.
Rotavirus vaccines: a story of success.
The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
The cost effectiveness of rotavirus vaccination in Iran
Introducing rotavirus vaccine into EPI program would be highly cost-effective public health intervention in Iran and a saving for the society with the same averted DALYs.
Nosocomial rotavirus infection: An up to date evaluation of European studies
The aim of this review is to summarize the epidemiology of both CARV and nRV in order to discuss the difficulty of a clear evaluation of the burden of the disease in absence of comparable data.
Primary care-based surveillance to estimate the proportion of rotavirus gastroenteritis among Latvian children below 5 years of age with acute gastroenteritis
It is underlines that RV is an important cause of AGE in children under 5 years old in Latvia and that the burden of disease of RVGE in primary care was substantial before inclusion of RV vaccination in the NIP.
Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland
RV vaccination in NIP has led to a major reduction of hospital admissions and clinic visits due to RVGE, but has had no effect on NVGE, which has become the leading cause of acute GE in children seen in hospital.


Effectiveness of the Pentavalent Rotavirus Vaccine in Preventing Gastroenteritis in the United States
In this first nationwide study evaluating VE under conditions of routine use, RV5 was highly effective in preventing RGE and AGE and in reducing health care resource utilization.
RotaTeq™: a three-dose oral pentavalent reassortant rotavirus vaccine
Results from a large clinical trial, as well as ongoing postmarketing surveillance, indicate that the 3-dose oral pentavalent RV vaccine (RotaTeq™) is safe and well tolerated, without evidence of increased risk of intussusception.
Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States: Review of the First 3 Years of Postlicensure Data
The implementation of routine childhood immunization againstRotavirus has rapidly and dramatically reduced the large health burden of rotavirus gastroenteritis in US children and continued monitoring of rotvirus diarrhea is needed to determine if immunity wanes as vaccinated children get older and to better quantify the indirect benefits of vaccination.
Decline in Cases of Rotavirus Gastroenteritis Presenting to The Children's Hospital of Philadelphia after Introduction of a Pentavalent Rotavirus Vaccine
The abrupt decline in rotavirus gastroenteritis cases during the 2007-2008 season likely resulted from vaccination, and protection rates appeared to have exceeded vaccination rates, so herd immunity may have contributed to some degree to the effectiveness of the vaccine.
Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule
Early evidence from the NIP in Australia has demonstrated high rotavirus coverage with both RV1 and RV5, supportive of both direct vaccine protection, as well as with indirect herd protection.
Rotavirus Vaccines in Belgium: Policy and Impact
A decrease in the number of rotavirus infections and a 4- to 6-week delay in the onset of disease and the peak of incidence in the postvaccination period coincides with the increased vaccine uptake.
Rotavirus Hospital Surveillance in the Era of Immunization
In New Orleans, G3P(8) is becoming a predominant strain of RV, and it is unclear whether this phenomenon represents natural variation or it is caused by introduction of vaccines.
Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States
Routine rotavirus vaccination would unlikely be cost-saving in the United States at present, but may still be considered a cost-effective intervention.
Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States
In this setting, a complete series of RV5 was highly effective against severe rotavirus AGE and partial immunization also conferred substantial protection.